Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Rumex Obtusifolius Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of IgE-mediated allergic conditions such as hay fever and allergic asthma through skin testing and subcutaneous immunotherapy.
Name
Rumex Obtusifolius Pollen
Raw Name
RUMEX OBTUSIFOLIUS POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
7
Variant Count
8
Last Verified
February 17, 2026
About Rumex Obtusifolius Pollen
Rumex Obtusifolius Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of IgE-mediated allergic conditions such as hay fever and allergic asthma through skin testing and subcutaneous immunotherapy.
Detailed information about Rumex Obtusifolius Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Rumex Obtusifolius Pollen.
Rumex Obtusifolius Pollen, commonly known as Broad-leaved Dock or Bitter Dock pollen, is a biological substance utilized in the field of clinical allergy and immunology. It belongs to the pharmacological class of Non-Standardized Pollen Allergenic Extracts [EPC]. This extract is derived from the microscopic pollen grains of the Rumex obtusifolius plant, a perennial weed in the Polygonaceae family. In a clinical context, these extracts are processed into sterile solutions intended for either diagnostic purposes (skin testing) or therapeutic intervention (allergen immunotherapy).
As a non-standardized extract, Rumex Obtusifolius Pollen is not measured in Bioequivalent Allergy Units (BAU) like some grass or mite extracts. Instead, its potency is typically expressed in terms of Weight/Volume (w/v) ratios or Protein Nitrogen Units (PNU). The FDA (Food and Drug Administration) regulates these extracts under the Center for Biologics Evaluation and Research (CBER), ensuring that the manufacturing process maintains consistent protein profiles, even though biological potency may vary between lots. Historically, dock pollen has been recognized as a significant contributor to late-spring and summer pollinosis (allergic rhinitis), often overlooked in favor of more prominent grass pollens.
The mechanism of action for Rumex Obtusifolius Pollen depends on its clinical application. In diagnostic testing, the extract is introduced into the epidermis (skin) to identify the presence of specific Immunoglobulin E (IgE) antibodies. If a patient is sensitized, the dock pollen allergens bind to IgE molecules already attached to mast cells in the skin. This binding triggers degranulation, releasing histamine and other inflammatory mediators, which results in a visible 'wheal and flare' reaction (a raised bump and surrounding redness) within 15 to 20 minutes.
In allergen immunotherapy (AIT), the extract is administered in gradually increasing doses to induce immunological tolerance. At the molecular level, this process is complex and involves several shifts in the immune system:
Traditional pharmacokinetics (absorption, distribution, metabolism, and excretion) do not apply to allergenic extracts in the same way they do to synthetic drugs.
Rumex Obtusifolius Pollen extracts are FDA-indicated for the following:
This extract is available in several sterile liquid forms:
> Important: Only your healthcare provider can determine if Rumex Obtusifolius Pollen is right for your specific condition. The selection of specific allergens for testing and treatment requires a detailed clinical history and physical examination by a board-certified allergist or immunologist.
Dosage for Rumex Obtusifolius Pollen is highly individualized and must be determined by a specialist based on the patient's sensitivity levels.
Rumex Obtusifolius Pollen is generally considered safe for use in children, though testing and treatment are rarely initiated in children under the age of 5 due to the difficulty of the procedure and the evolving nature of the immune system. Pediatric dosing follows the same individualized 'start low and go slow' principle used in adults. Healthcare providers must carefully monitor pediatric patients for systemic reactions, as children may have more difficulty communicating early symptoms of anaphylaxis.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared via the kidneys in a manner that would lead to toxicity. However, the patient's overall health status should be stable before administration.
No dosage adjustments are necessary for hepatic impairment. The metabolic processing of pollen proteins is independent of primary hepatic metabolic pathways (like the CYP450 system).
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the primary treatment for a severe reaction) in patients with heart disease must be weighed against the benefits of immunotherapy.
Rumex Obtusifolius Pollen extracts are never for self-administration. They must be administered by a trained healthcare professional in a clinical setting equipped to handle anaphylaxis.
If an immunotherapy dose is missed, the next dose may need to be reduced depending on how much time has passed.
An 'overdose' in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level. This can occur due to dosing errors or if the patient's sensitivity has increased (e.g., during peak pollen season). Signs of overdose include severe local swelling, hives, wheezing, or a drop in blood pressure. Immediate treatment with epinephrine and other emergency measures is required.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter your treatment schedule or self-administer these extracts without direct medical guidance.
Most patients receiving Rumex Obtusifolius Pollen will experience some form of local reaction.
> Warning: Stop taking Rumex Obtusifolius Pollen and call your doctor immediately or seek emergency care if you experience any of the following symptoms of a systemic reaction (anaphylaxis):
There are no known long-term 'toxic' effects of Rumex Obtusifolius Pollen extracts. Unlike many medications, these are biological proteins that do not accumulate in organs. The primary long-term consideration is the successful modulation of the immune system. In rare cases, patients may develop new sensitivities to other components in the extract (such as preservatives), though this is uncommon.
Allergenic extracts, including Rumex Obtusifolius Pollen, carry a significant warning regarding the risk of Anaphylaxis.
Report any unusual symptoms, especially those occurring hours after the injection (late-phase reactions), to your healthcare provider.
Rumex Obtusifolius Pollen is intended for use only by physicians specializing in allergy. It is not a standard 'medication' but a biological extract that interacts directly with the immune system. Safety depends on accurate diagnosis and careful dose escalation.
No FDA black box warnings specifically for Rumex Obtusifolius Pollen exist beyond the general class warning for all allergenic extracts. The class-wide warning emphasizes that these products can cause severe anaphylaxis. It further states that patients should be informed of the risks and should be capable of self-administering epinephrine if a delayed reaction occurs after they leave the clinic.
Generally, there are no restrictions on driving or operating machinery after a test or injection, provided the patient has completed their 30-minute observation period and feels well. However, if a systemic reaction occurs or if the patient feels lightheaded, they should not drive.
There is no direct chemical interaction between alcohol and dock pollen extract. However, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically accelerate the absorption of the allergen and increase the risk of a reaction. It is generally advised to avoid alcohol for several hours after an injection.
If immunotherapy is discontinued, the patient will gradually lose the immunological tolerance built up during treatment. There is no 'withdrawal syndrome,' but allergy symptoms may return upon exposure to Rumex Obtusifolius Pollen in the environment. Tapering is not required; the treatment is simply stopped.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Rumex Obtusifolius Pollen.
There are few absolute contraindications for drug combinations, but the following are critical:
There are no known direct food interactions with Rumex Obtusifolius Pollen. However, patients with 'Oral Allergy Syndrome' may find that certain foods (like rhubarb or other members of the Polygonaceae family) cause itching in the mouth if they are highly sensitive to dock pollen. This is due to cross-reactivity between proteins.
There is no documented evidence of interactions with St. John’s Wort, ginkgo, or other common supplements. However, any supplement that affects the immune system or blood pressure should be disclosed to the allergist.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, heart rhythm, or depression.
Rumex Obtusifolius Pollen must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients allergic to Rumex Obtusifolius may also show sensitivity to other species in the Rumex genus (such as Rumex acetosella or Sheep Sorrel) and potentially other members of the Polygonaceae family. This 'cross-reactivity' occurs because these plants share similar protein structures (homologous allergens).
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Rumex Obtusifolius Pollen.
Rumex Obtusifolius Pollen is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known if the extract can cause fetal harm.
It is not known whether pollen allergens or the antibodies produced during treatment are excreted in human milk. However, since these are naturally occurring proteins and the amount administered is very small, it is generally considered safe to continue immunotherapy while breastfeeding. No adverse effects on nursing infants have been documented.
Immunotherapy with dock pollen is approved for pediatric use, typically for children aged 5 and older. The efficacy is well-documented in reducing the progression from allergic rhinitis to asthma (the 'allergic march'). Special care must be taken to ensure the child can cooperate with the injection and observation process. Growth and development are not affected by allergenic extracts.
In patients over 65, the primary concern is the presence of co-morbidities such as coronary artery disease or COPD. The elderly may have a reduced physiological reserve to survive a severe systemic reaction. Pharmacokinetic changes related to age (reduced renal/hepatic function) are not relevant for this biological product.
There are no specific guidelines or dose adjustments for patients with kidney disease. The proteins in the extract are broken down locally and systemically by proteases, and do not rely on renal filtration for clearance.
No adjustments are required for patients with liver disease. The liver's metabolic capacity does not influence the safety or efficacy of subcutaneous allergenic extracts.
> Important: Special populations, particularly pregnant women and those with heart disease, require an individualized medical assessment to ensure the benefits of treatment outweigh the risks.
Rumex Obtusifolius Pollen functions as an immunomodulator. It does not target a specific receptor like a traditional drug; instead, it provides a controlled exposure to the allergens (primarily proteins and glycoproteins) that trigger the patient's immune system.
Upon injection, the allergens are taken up by Antigen-Presenting Cells (APCs) such as dendritic cells. These cells process the pollen proteins into peptides and present them to T-lymphocytes. In an allergic individual, this usually results in a Th2 response. Immunotherapy forces the system to produce Regulatory T-cells (Tregs). These Tregs produce inhibitory cytokines like IL-10, which tells B-cells to stop producing IgE and start producing IgG4. This shift from an IgE-mediated inflammatory response to an IgG4-mediated 'blocking' response is the hallmark of successful treatment.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Percutaneous) |
| Protein Binding | N/A (Processed by immune cells) |
| Half-life | Minutes (Allergen) / Weeks (Induced Antibodies) |
| Tmax | 15-30 minutes (Local reaction) |
| Metabolism | Proteolytic degradation |
| Excretion | Not renally excreted as intact protein |
Rumex Obtusifolius Pollen is categorized as a Non-Standardized Pollen Allergenic Extract [EPC]. It is grouped with other weed pollen extracts such as Ragweed, Sagebrush, and Pigweed, though it is botanically distinct.
Common questions about Rumex Obtusifolius Pollen
Rumex Obtusifolius Pollen extract is primarily used for the diagnosis and treatment of seasonal allergies caused by the Broad-leaved Dock plant. In a clinical setting, an allergist uses a small amount of the extract for skin prick testing to confirm if a patient is allergic to this specific weed. If the allergy is confirmed and symptoms are severe, the extract is then used in 'allergy shots' (immunotherapy). This process involves giving the patient gradually increasing amounts of the pollen to help their immune system build up a tolerance. Over time, this can significantly reduce symptoms like sneezing, itchy eyes, and asthma flares.
The most common side effects are localized to the area where the extract was applied or injected. Most patients will experience redness, itching, and a small raised bump (wheal) at the site, which usually disappears within a few hours. Some patients may experience a 'large local reaction,' where the swelling at the injection site becomes several inches wide and lasts for a day or two. While rare, systemic reactions can occur, affecting the whole body. These can include hives, nasal congestion, or more serious symptoms like wheezing and throat swelling, which require immediate medical attention.
While there is no direct chemical interaction between alcohol and the pollen extract, healthcare providers generally advise against drinking alcohol for several hours after receiving an allergy injection. Alcohol causes blood vessels to dilate (expand), which could theoretically cause the allergen to be absorbed into your system more quickly, potentially increasing the risk of a systemic allergic reaction. Additionally, alcohol can mask the early symptoms of a reaction or make you less aware of them. It is best to wait until the following day to consume alcohol to ensure you remain stable after your treatment.
Rumex Obtusifolius Pollen is generally not started during pregnancy because of the risk of a severe allergic reaction (anaphylaxis), which could be dangerous for both the mother and the developing baby. However, if a woman is already on a stable 'maintenance dose' of immunotherapy and becomes pregnant, most allergists believe it is safe to continue the treatment at that same dose. The decision is always individualized based on the severity of the mother's allergies. You should inform your allergist immediately if you become pregnant or are planning to conceive so they can adjust your treatment plan accordingly.
For diagnostic purposes, the extract works almost immediately, producing a skin reaction within 15 to 20 minutes. However, when used as a treatment (immunotherapy), it takes much longer to see the benefits. Most patients begin to notice a decrease in their allergy symptoms after 6 to 12 months of consistent injections. The full effect is typically reached after the patient has been on a maintenance dose for a year or more. A complete course of treatment usually lasts between 3 and 5 years to ensure that the immune system changes are long-lasting.
Yes, you can stop taking Rumex Obtusifolius Pollen injections suddenly without experiencing any withdrawal symptoms like you might with certain medications. However, stopping the treatment before the recommended 3-to-5-year period means your allergy symptoms are likely to return over time. The immune system needs consistent exposure over several years to 'learn' not to react to the dock pollen. If you need to stop treatment due to side effects, cost, or scheduling issues, discuss it with your allergist to see if a modified schedule or a different treatment option might be available.
If you miss a scheduled immunotherapy injection, you should contact your allergist's office as soon as possible to reschedule. Do not try to 'double up' on your next dose. If you only miss a week or two, your doctor may give you your usual dose. However, if you miss several weeks, your immune system's sensitivity may have changed, and your doctor will likely need to reduce the dose for your next injection to ensure safety. Missing too many doses may require you to restart the 'build-up' phase of your treatment from a lower concentration.
There is no scientific evidence or clinical data suggesting that Rumex Obtusifolius Pollen extracts cause weight gain. The extract consists of a very small amount of natural proteins that are processed by the immune system and do not affect your metabolism, appetite, or fat storage. If you experience weight changes while undergoing immunotherapy, it is likely due to other factors such as lifestyle changes, other medications (like oral steroids sometimes used for allergies), or unrelated medical conditions. You should discuss any unexpected weight changes with your primary care physician.
Rumex Obtusifolius Pollen can be taken alongside most medications, but there are some very important exceptions. You must tell your allergist if you are taking beta-blockers (for heart or blood pressure) or MAO inhibitors (for depression), as these can make allergic reactions much more dangerous and harder to treat. Additionally, if you are taking antihistamines, you will need to stop them for several days before a skin test, as they can block the test results. Most other routine medications for cholesterol, diabetes, or birth control do not interact with pollen immunotherapy.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for pills. Because Rumex Obtusifolius Pollen is a biological product derived from natural sources, different manufacturers may produce their own versions of the extract. These are generally considered interchangeable by allergists, but they are not 'generics' in the traditional sense. Each manufacturer must follow strict FDA guidelines to ensure the protein content is consistent. Your allergist will select a high-quality extract from a reputable laboratory for your testing and treatment.